MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

Written on the 15 May 2015 by Jenna Rathbone

MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

MEDIGARD'S (ASX:MGZ) unique blood collection device is yet to hit shelves, despite two announcements that initial sales for the medical instrument would commence in March of this year.

The Gold Coast company, which has again delayed the launch, says it is a result of market resistance to primary packaging and unexpected delays occurring while trying to implement a solution.

Although significant resources had been employed to produce a blood collection device (BCD) that requires no primary packaging, it is now expected that sales for the BCD will commence in June.

Medigard says at the time of announcing a March launch date it was convinced the changes made to the device to allow it to be manufactured and distributed without primary packaging would not cause significant further delays.

"Although the changes are not obvious from appearance, the subtle design changes and the changes to the materials used for the moulding of some key components has also meant that manufacturing equipment has had to be modified," says Medigard in a statement to shareholders.

"As is the nature of medical device design changes, there has had to be changes to the regulatory approvals for the BCD.  Both of these factors have caused unexpected delays."

Small-scale manufacture is currently under way and the BCD is expected to launch in Taiwan and Asia Pacific in June and the US and Europe in July.

Medigard says 300,000 BCDs are currently in production and will be distributed for clinical evaluations. A clinical study is to be coordinated in the UK.

The Medigard BCD features vacuum technology to capture the needle after blood has been collected.  This is expected to prevent needle-stick injury by eliminating human contact with used needles and avoids potential aerosoling, a dangerous spray of fluid getting into the air when a needle is retracted.

In 2013, Medigard secured an exclusive license agreement with Shanghai Sol-Millennium Medical Products Co to manufacture and distribute its BCD and Blood Flash Needle.

Medigard has patents for the BCD in Australia, the US, Japan, Canada and Europe while the 3ml vacuum retractable syringe has patents in South Africa, the US, Australia, China, Japan and Canada.

Medigard was floated in 2004 and its board includes Don Channer as chairman and Peter Clark as director.

Shares closed at .085c. 


Author: Jenna Rathbone
About: Jenna Rathbone is a Queensland-based journalist who writes on a range of issues including business and property affairs and social issues.
Connect via: Twitter

Latest News

CROMWELL TRADES STEADILY IN FIRST HALF

CROMWELL Property Group has maintained a steady operating profit at $0.045 per security in the first half of FY17,...

WHY NEXTDC'S STOCK IS SOARING

AFTER posting its interim result, NEXTDC (ASX: NXT) gained more than 12 per cent on the stock market before noon.
...

PWR PROFIT CRASHES AS DOLLAR RISES AND COSTS MOUNT

A RISING Aussie dollar has offset PWR Holdings Limited's (ASX:PWH) overseas growth in the last half, forcing a...

SUPER RETAIL GROUP RESULTS SHINE ACROSS THE BOARD

A WELL-planned and executed half has paid off for Super Retail Group (ASX:SUL) as it posts a net profit result up ...

Related News

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

WHY EMPLOYEE-OWNED COMPANIES ARE BEATING ASX200 SHARE PRICES

EMPLOYEE-owned companies command a higher share price than their publicly listed peers, reaping a 17 per cent prem...

RISE OF THE MACHINES HAS WORKERS SWEATING

UP TO 3.8 million Australian workers are fearful their job may soon be terminated by a robot, a new survey has shown....

LESS TALK, MORE SMALL BUSINESS ACTION IN 2017

THE future growth and prosperity of Australian SMEs could be undermined if governments lose sight of the sector...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter